| Téléchargement | - Voir la version finale : Optimal expression, function, and immunogenicity of an HIV-1 vaccine derived from the approved Ebola vaccine, rVSV-ZEBOV (PDF, 4.5 Mio)
- Voir les données supplémentaires : Optimal expression, function, and immunogenicity of an HIV-1 vaccine derived from the approved Ebola vaccine, rVSV-ZEBOV (PDF, 208 Kio)
|
|---|
| DOI | Trouver le DOI : https://doi.org/10.3390/vaccines11050977 |
|---|
| Auteur | Rechercher : Azizi, Hiva1; Rechercher : Knapp, Jason P.Identifiant ORCID : https://orcid.org/0000-0003-2147-6000; Rechercher : Li, Yue; Rechercher : Berger, Alice; Rechercher : Lafrance, Marc-AlexandreIdentifiant ORCID : https://orcid.org/0000-0002-6680-5691; Rechercher : Pedersen, Jannie; Rechercher : de la Vega, Marc-Antoine; Rechercher : Racine, TrinaIdentifiant ORCID : https://orcid.org/0000-0001-6370-8661; Rechercher : Kang, Chil-Yong; Rechercher : Mann, Jamie F. S.; Rechercher : Dikeakos, Jimmy D.; Rechercher : Kobinger, Gary; Rechercher : Arts, Eric J. |
|---|
| Affiliation | - Conseil national de recherches du Canada. Thérapeutique en santé humaine
|
|---|
| Bailleur de fonds | Rechercher : National Institutes of Health; Rechercher : Canadian Institutes of Health Research; Rechercher : Canada Research Chair; Rechercher : Canada Foundation for Innovation |
|---|
| Format | Texte, Article |
|---|
| Sujet | human immunodeficiency virus type 1 (HIV-1); vesicular stomatitis virus (VSV) vector; HIV-1 Envelope glycoprotein; Ebola virus glycoprotein |
|---|
| Résumé | Vesicular stomatitis virus (VSV) remains an attractive platform for a potential HIV-1 vaccine but hurdles remain, such as selection of a highly immunogenic HIV-1 Envelope (Env) with a maximal surface expression on recombinant rVSV particles. An HIV-1 Env chimera with the transmembrane domain (TM) and cytoplasmic tail (CT) of SIVMac239 results in high expression on the approved Ebola vaccine, rVSV-ZEBOV, also harboring the Ebola Virus (EBOV) glycoprotein (GP). Codon-optimized (CO) Env chimeras derived from a subtype A primary isolate (A74) are capable of entering a CD4+/CCR5+ cell line, inhibited by HIV-1 neutralizing antibodies PGT121, VRC01, and the drug, Maraviroc. The immunization of mice with the rVSV-ZEBOV carrying the CO A74 Env chimeras results in anti-Env antibody levels as well as neutralizing antibodies 200-fold higher than with the NL4-3 Env-based construct. The novel, functional, and immunogenic chimeras of CO A74 Env with the SIV_Env-TMCT within the rVSV-ZEBOV vaccine are now being tested in non-human primates. |
|---|
| Date de publication | 2023-05-12 |
|---|
| Maison d’édition | MDPI |
|---|
| Licence | |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | 65bf7e51-439f-47b4-92e2-43dcbaf415b9 |
|---|
| Enregistrement créé | 2023-08-15 |
|---|
| Enregistrement modifié | 2023-08-15 |
|---|
